




## New approaches to Epidemiological Risk Assessment of Low Level Exposures to Air Pollution

Paolo Vineis , Imperial College , London

- **Acknowledgments: my research is funded by the European Commission (Exposomics and Lifepath grants)**
- **I have no conflicts of interest to declare**

# LOST YEARS

Air pollution around the world leads to around 4.5 million deaths and 120 million years of life lost each year.



**1** Since 1970, the **UK** death rate from air pollution has reduced by 30% through EU legislation.


**2** In **West Africa**, desert dust adds to air pollution.

**3** **India's** air quality has worsened fastest in the past decade.


**4** **China's** air quality started improving in 2010.

Areas with population data are shown; an average is assumed for countries without detailed data.

## Heterogeneity of exposure in European cities: PM<sub>2.5</sub> in the ESCAPE project.




**Total mortality in relation to PM<sub>2.5</sub> (Beelen R et al 2014, Effects of long-term exposure to air pollution on natural-cause mortality: an analysis of 22 European cohorts within the multicentre ESCAPE project. Lancet. 2014 Mar 1;383(9919):785-95)**





# Traffic contributions to the London Airshed







**NOx background:** Cars (21.6%), LGVs (7.1%), HGVs (8.8%), buses (10.6%).  
Total traffic contribution: 48.6%.

**NOx roadside:** Cars (28.3%), LGVs (11.1%), HGVs (10.1%), buses (30.6%).  
Total traffic contribution: 80.1%.


**PM<sub>2.5</sub> background:** Cars (2.9%), LGVs (1.1%), HGVs (0.9%), buses (0.3%), vehicle non-exhaust (5.8%).  
Total traffic contribution: 11.0%.

**PM<sub>2.5</sub> roadside:** Cars (7.0%), LGVs (2.9%), HGVs (2.3%), buses (2.2%), vehicle non-exhaust (14.7%).  
Total traffic contribution: 29.1%.

# Contribution of microenvironment to UFP exposure in The Netherlands




# Exposome




## RISK OF DISEASE AND ADVERSE OUTCOMES








# Silicone wristbands



PAHS measured with wristbands

O'Connell et al., 2014, Silicone Wristbands as Personal Passive Samplers, ES&T, 48 : 3327-3335






## OXIDATIVE POTENTIAL OF AIR POLLUTION

**Gulliver et al, Environ Res 2017.** Boxplots of measured annual average concentration (% consumption) of  $OP^{AA}$  and  $OP^{GSH}$  by study are


# Internal exposome : “OMICS”







## An example of questions: NO<sub>2</sub> - a surrogate for traffic pollutants?

- **Still no robust basis** for setting a value for NO<sub>2</sub> through any direct toxic effect.
- Does NO<sub>2</sub> at ambient levels have any detectable toxicity on the human lung?
- Which aspects/components of combustion mixtures are responsible for the adverse health effects observed in epidemiological studies?
- Is NO<sub>2</sub> able to synergise with other pollutants e.g. PM/allergen (role as an effect modifier)?






# Health endpoint



# Meet-in-the-middle


**CVD:** One inflammatory protein (Interleukin-17), and two DNA methylation inflammatory pathways ('ROS/Glutathione/Cytotoxic granules' and 'Cytokine signaling') were significantly associated with both exposure to air pollution and the risk of CHD, fulfilling the 'meet-in-the-middle' hypothesis.

*Fiorito et al, Environmental Molecular Mutagenesis, 2017*




**Results from molecular mediation are consistent with air pollution impacting on both asthma and CVD via pro-inflammatory and oxidative stress pathways, albeit different molecules may be involved in the two groups of diseases.**

## SAPALDIA



Search for MITM pathways




Linoleate metabolism for PM2.5 and UFP  
Glycerophospholipid metabolism for UFP

Laboratory confirmation of chemical identities within the MITM pathways

Linoleate ( $m/z=281.2464$ ;  $RT=7.283$ ) was confirmed

## EPIC



Validation\*\*

Validation\*\*

Search for MITM pathways



Fatty acid activation for PM2.5  
Linoleate metabolism for PM2.5  
Glycosphingolipid metabolism for UFP  
Carnitine shuttle for NO2

Laboratory confirmation of chemical identities within the MITM pathways

Carnitine ( $m/z=162.1128$ ;  $RT=0.601$ ) and Stearoylcarnitine ( $m/z=428.373$ ;  $RT=6.479$ ) were confirmed




# Fingerprints of exposure: Adductomics

New technologies may serve the purpose of increasing sensitivity and specificity in identifying relevant chemicals in mixtures, low-dose effects and dose-response : adductomics


- Pilot study of smokers and non-smokers (n=40)
- PISCINA 2 – before and after swimming in a chlorinated pool (n=120)
- PEM study – air pollution exposure measured by personal monitors (n=584)
- Oxford Street 2 – before and after 2 hours spent in a highly polluted street (n=354)
- Lung cancer study – nested case-control of EPIC cohort (n=400)

*Courtesy G Preston and Steve Rappaport*  
 - Untargeted methodology. Data from two different (complementary) MS-based platforms. Semi-synthetic control adduct detected by both groups




## Effects of components in a mixture

Metabolomic signatures of different components of air pollution (Oxford Street study, left, and TAPAS, right) (Bonferroni significance)



## Mixtures: Transcriptomics



miRNA work in relation to air pollution shows that air pollutants impact several pathways via miRNA activation that in turn are relevant to the multi-organ toxicity of air pollution




**Pollutant-specific miRNAs associated with TRAP exposure.** The figure shows the overlap as well as the specificity of the pollutant-specific miRNAs associated with exposure to NO<sub>2</sub>, UFP, PM<sub>2.5</sub>, BC and PM<sub>10</sub> of the included subjects in Hyde Park and Oxford Street. **Julian Krauskopf et al, 2018**

# Low levels of exposure in EXPOsOMICS

PM 10 by cohort (left) and metabolomic signals (right) in Piccoli+ (very high exposure levels) and in Environage (low exposure levels) Bonferroni threshold -  $p = 1.63 \times 10^{-4}$







## Philosophy of co-benefits

# Acknowledgements



**Exposomics Funder** - European Union FP7

**Lifepath Funder** – European Union H2020

## **Collaborators Exposomics (for current analyses)**

**ICL** – Paolo Vineis, Marc Chadeau-Hyam, John Gulliver, Karin van Veldhoven, Florence Guida, Michelle Plusquin, Michaela Dijmarescu, Terrence Simmons, Paul Cullinan, Fan Chun

**KCL** – George Preston, David Phillips

**CREAL** – Manolis Kogevinas, Cristina Villanueva, Laia Font-Ribera, Mark Nieuwenhuijsen

**BASEL Swiss TPH** – Nicole Probst-Hensch

**HuGeF** – Alessio Naccarati

**IARC** – Augustin Scalbert, Pekka Keski Rahkonen, Dinesh Barupal

**Utrecht University** – Roel Vermeulen, Jelle Vlaanderen, Lutzen Portengen

**Genedata** – Hans Gmuender

## **Collaborators Lifepath (WP leaders)**

**Rotterdam University** - Johan Mackenbach

**Lausanne University** - Silvia Stringhini

**HuGeF** - Silvia Polidoro, Giovanni Fiorito

**ICL** - Marc Chadeau-Hyam

**KCL** - Mauricio Avendano

**Toulouse University** - Michelle Kelly Irving

**UCL** - Michael Marmot, Mika Kivimaki

**Zadig** - Luca Carra

**Thanks to Soterios Kyrtopoulos, Steve Rappaport, Federica Russo, Martyn Smith, Duncan Thomas and Chris Wild**